Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15360282 | 0.78 | ALDH1A1 (0.43) | HSD17B10ALDH1A1KDM4EALOX15GRM5 | |
| SCHEMBL26151668 | 0.78 | — | — | |
| SCHEMBL19251314 | 0.78 | GRM5 (0.40) | HSD17B10ALDH1A1KDM4EALOX15GRM5 | |
| SCHEMBL22752392 | 0.78 | GRM5 (0.40) | HSD17B10ALDH1A1KDM4EALOX15GRM5 | |
| SCHEMBL26151666 | 0.75 | — | — | |
| SCHEMBL19801728 | 0.75 | TRPV1 (0.42) | ALDH1A1GRM5MEN1MAPK1KMT2A | |
| SCHEMBL13947610 | 0.75 | TDP1 (0.39) | ALDH1A1TSHR | |
| SCHEMBL19254948 | 0.74 | GRM5 (0.38) | HSD17B10ALDH1A1KDM4EALOX15GRM5 | |
| SCHEMBL19251394 | 0.74 | GRM5 (0.38) | HSD17B10ALDH1A1KDM4EALOX15GRM5 | |
| SCHEMBL13007624 | 0.74 | HDAC6 (0.48) | GRM5CYP1A2CYP2D6MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | ARRAY BIOPHARMA INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-10793549-B2 | Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-10-06 | — | — | US | disclosed |
| US-10654828-B2 | Indole derivatives and uses thereof | NOVARTIS AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20130225581-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198273-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | HSD17B10 4521/4885ALDH1A1 3828/4885KDM4E 1582/4885 |
| US-20210244721-A1 | SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF | AR, KLK3, BRDT | HSD17B10 612/4885ALDH1A1 3667/4885KDM4E 2146/4885 |
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | HSD17B10 640/4885ALDH1A1 1445/4885KDM4E 2957/4885 |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | HSD17B10 356/4885ALDH1A1 1898/4885KDM4E 2371/4885 |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | HSD17B10 4532/4885ALDH1A1 2306/4885KDM4E 728/4885 |
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | HSD17B10 356/4885ALDH1A1 1898/4885KDM4E 2371/4885 |
| US-20130225581-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC DERIVATIVE | FGFR3, FGFR1, FGFR4 | HSD17B10 1922/4885ALDH1A1 2684/4885KDM4E 618/4885 |
| US-10889589-B2 | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain | TK1, UACA, TDP1 | HSD17B10 4687/4885ALDH1A1 3388/4885KDM4E 2186/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | HSD17B10 3793/4885ALDH1A1 999/4885KDM4E 3363/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | HSD17B10 626/4885ALDH1A1 1573/4885KDM4E 2926/4885 |
| US-20120245174-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, RAF1 | HSD17B10 3793/4885ALDH1A1 999/4885KDM4E 3363/4885 |
| US-10654828-B2 | Indole derivatives and uses thereof | MYLK2, MYOF, MUSK | HSD17B10 3113/4885ALDH1A1 1676/4885KDM4E 2754/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | HSD17B10 404/4885ALDH1A1 1726/4885KDM4E 2335/4885 |
| US-10793549-B2 | Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof | STS, SULT2A1, CYP2A13 | HSD17B10 550/4885ALDH1A1 579/4885KDM4E 2911/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | HSD17B10 2786/4885ALDH1A1 1828/4885KDM4E 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.